![](https://ml.globenewswire.com/media/1644a38b-bed9-4a76-96fa-d57dd028e650/small/medicenna-jpg.jpg)
Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones
- Disease control rate (DCR) of 78% (7 of 9) in combination escalation arm of MDNA11 with Merck’s (known as MSD outside of Canada and the US) KEYTRUDA® (pembrolizumab) in ongoing Phase 1/2 ABILITY-1 trial including one complete response, one partial …